A familial Alzheimer's genetic panel is a blood test that checks three genes — APP, PSEN1, and PSEN2 — for mutations that cause early-onset Alzheimer's disease. When dementia symptoms are already progressing, the test's main value is confirming or ruling out a specific inherited cause, which shapes decisions for the patient and their relatives. These genes follow autosomal dominant inheritance, meaning a single mutated copy passed from one parent is enough to cause disease, and together they explain a small share of all Alzheimer's cases but roughly 11% of cases that begin before age 65, according to a peer-reviewed early-onset Alzheimer's genetics review. The test is most useful for families with a documented pattern of early-onset disease across generations, not for typical late-onset Alzheimer's.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Accurate Is the Panel Once Symptoms Have Started?
- Who Should Be Tested First in a Family
- What Pre-Test Counseling Involves for a Symptomatic Patient
- What a Confirmed Result Opens Up
- Will Insurance Cover the Panel?
- Frequently Asked Questions
How Accurate Is the Panel Once Symptoms Have Started?
Accuracy depends heavily on family history. ARUP Laboratories, a clinical lab that runs this panel, reports identifying a causative variant in about 60–80% of cases where there is a clear family history of early-onset Alzheimer's, with sensitivity dropping as the age of symptom onset increases, according to ARUP's test fact sheet. Among the variants the panel does find, PSEN1 accounts for roughly 20–70% of cases, APP for 10–15%, and PSEN2 for about 5%, leaving 20–40% of familial early-onset cases without an identified cause even after testing, per the same ARUP documentation. That gap matters: a negative result lowers the odds of a known genetic cause but does not eliminate it.
A negative panel also does not rule out a heritable cause of dementia outright, because the assay only examines coding regions and the boundaries between introns and exons. It can miss larger structural changes such as deletions or duplications, a limitation ARUP's documentation specifically flags as a reason a "normal" result is not the same as "no genetic cause," per ARUP's fact sheet. Age at symptom onset also helps interpret a positive result. PSEN2-linked disease typically starts later, in a person's 50s or 60s, while APP and PSEN1 mutations more often produce onset in the 30s or 40s, according to a PSEN2 clinical genetics summary. A clinician will weigh a positive finding against the patient's actual symptom timeline before treating it as the explanation.
Who Should Be Tested First in a Family
When one family member already has dementia symptoms, the standard approach is to test that person before testing any unaffected relatives. Identifying the specific mutation in the symptomatic patient first gives the family a known target to check for in others, rather than running broad panels on everyone, per a summary of the ACMG/NSGC joint practice guideline.
Testing asymptomatic relatives follows a separate, more cautious protocol adapted from predictive testing used in Huntington's disease, and it is mainly offered when someone needs the information for reproductive decisions, such as whether to pursue prenatal testing or use assisted reproduction to avoid passing on the mutation. That distinction keeps genetic testing from being offered reflexively to healthy relatives who may not want or need the result.
What Pre-Test Counseling Involves for a Symptomatic Patient
The American College of Medical Genetics and the National Society of Genetic Counselors jointly issued the reference guideline for this testing in 2011, and it states that testing should always be paired with genetic counseling before and after the test, not ordered as a standalone lab request, according to the ACMG/NSGC joint practice guideline. For a patient who is already symptomatic, the guideline calls for a legal guardian or family member to be present during pre-test counseling.
Counselors are also directed to watch for conflicts of interest when it's a relative, rather than the patient, who initiates the request, according to the guideline as reported by Newswise. If the patient appears reluctant or unable to give informed consent, the guideline directs counselors not to proceed with testing. DNA banking — storing a blood or tissue sample for possible testing later — is offered instead, preserving the option without forcing a decision the patient cannot meaningfully make.
What a Confirmed Result Opens Up
A confirmed mutation in APP, PSEN1, or PSEN2 can open the door to research studies built specifically around genetic risk. The Dominantly Inherited Alzheimer Network's treatment trial, for example, enrolls confirmed mutation carriers — or people known to carry a 50% familial risk — within roughly 15 years before to 10 years after their predicted or actual symptom onset, using the specific mutation type or family history to estimate that window, according to the DIAN-TU-001 trial protocol.
This means a positive result is not only diagnostic information; it can be the entry point to a specific research pathway unavailable to someone without a confirmed mutation. Families interested in this route typically need the lab report naming the exact variant before a trial team can assess eligibility.
Will Insurance Cover the Panel?
Coverage varies by insurer and depends on the clinical picture. One example, a South Carolina Blue Cross Blue Shield medical policy, treats diagnostic APP/PSEN1/PSEN2 testing as medically necessary for a symptomatic person with suspected early-onset disease and an unclear family history, according to the insurer's medical policy CAM 287.
The same policy classifies routine APOE testing — a separate gene linked to late-onset Alzheimer's risk, outside of specific drug-related uses — as not medically necessary. That distinction is worth checking against a specific insurer's policy before scheduling the panel, since the three-gene panel and APOE testing are often confused but reviewed under different coverage rules.
- Confirm with the insurer which specific genes are covered, since APOE and the APP/PSEN1/PSEN2 panel are evaluated separately.
- Bring documented family history details to the counseling visit; coverage decisions and test interpretation both depend on it.
- Ask whether a guardian or family member needs to attend the pre-test counseling session if the patient's symptoms raise consent questions.
Frequently Asked Questions
Can a negative panel result mean a family's dementia still has a genetic cause?
Yes. The assay only checks coding regions and exon-intron boundaries, so it can miss larger deletions or duplications, per ARUP Laboratories' test documentation.
Should an asymptomatic family member be tested before the symptomatic one?
No. Guidelines call for testing the symptomatic person first to identify the family's specific mutation before testing relatives without symptoms.
You Might Also Like
- Familial Alzheimer’s Genetic Panel When Initial Results Are Borderline: Accuracy, Preparation, and Next Steps
- Familial Alzheimer’s Genetic Panel When Dementia Symptoms Progress: What It Measures and What It Misses
- Questions to Ask About Familial Alzheimer’s Genetic Panel When Dementia Symptoms Progress
